(Q44503701)

3 December 2017

title

Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions (English)

1 reference

3 December 2017

0 references

Eva Bredberg

1

1 reference

3 December 2017

Tommy B Andersson

2

1 reference

3 December 2017

Lars Frison

3

1 reference

3 December 2017

Annelie Thuresson

4

1 reference

3 December 2017

Susanne Johansson

5

1 reference

3 December 2017

Maria Eriksson-Lepkowska

6

1 reference

3 December 2017

Marita Larsson

7

1 reference

3 December 2017

Ulf G Eriksson

8

1 reference

3 December 2017

publication date

1 January 2003

1 reference

Clinical Pharmacokinetics

3 December 2017

published in

1 reference

3 December 2017

volume

42

1 reference

3 December 2017

issue

8

1 reference

3 December 2017

page(s)

765-777

1 reference

A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibiti

3 December 2017

cites work

1 reference

12 December 2020

Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms

1 reference

12 December 2020

Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.

1 reference

12 December 2020

Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat

1 reference

12 December 2020

Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat

1 reference

12 December 2020

Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes

1 reference

12 December 2020

Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study

1 reference

12 December 2020

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

1 reference

12 December 2020

Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research

1 reference

12 December 2020

Is diclofenac a valuable CYP2C9 probe in humans?

1 reference

12 December 2020

Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial

1 reference

12 December 2020

A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.

1 reference

12 December 2020

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans

1 reference

12 December 2020

Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry.

1 reference

12 December 2020

Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects

1 reference

12 December 2020

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

1 reference

12 December 2020

Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.

1 reference

12 December 2020

The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis

1 reference

12 December 2020

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

1 reference

12 December 2020

Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s

1 reference

12 December 2020

Role of cytochrome P450 enzymes in drug-drug interactions.

1 reference

12 December 2020

10.2165/00003088-200342080-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

3 December 2017

1033664072

0 references

1 reference